| Dr David B Rosania, MD | |
|
908 N Elm St Ste 301, Hinsdale, IL 60521-3625 | |
| (630) 794-9999 | |
| (630) 794-9998 |
| Full Name | Dr David B Rosania |
|---|---|
| Gender | Male |
| Speciality | Physical Medicine And Rehabilitation |
| Experience | 33 Years |
| Location | 908 N Elm St Ste 301, Hinsdale, Illinois |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1346281888 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208100000X | Physical Medicine & Rehabilitation | 036109067 (Illinois) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Thorek Memorial Hospital | Chicago, IL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Thorek Memorial Hospital | 4981593399 | 31 |
| Advanced Physicians Sc | 6103879713 | 9 |
| Northwest Neurology, Ltd | 8729069158 | 34 |
News Archive
St. Jude Children's Research Hospital scientists looking for drugs to improve survival of children with high-risk neuroblastoma found a promising candidate in CX-5461.
Replacing confusing language and icons on standard warnings labels for prescription medicine and listing only the most important warnings could make a big difference in how well patients understand the instructions that are critical to their health, according to a new study from Northwestern University Feinberg School of Medicine.
Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced the initiation of a Phase 2 clinical trial with ACE-031 in patients with Duchenne Muscular Dystrophy (DMD), a fatal neuromuscular disease. ACE-031 is an investigational protein therapeutic that builds muscle and increases strength by inhibiting signaling of a cell surface receptor called the activin receptor type IIB (ActRIIB).
DigiPath, Inc., the independent digital pathology and cannabis testing, education, and media firm, has entered into a preferred supplier marketing and resource-sharing agreement with Blue Line Protection Group.
Adding social gaming elements to a behavior tracking program led people to exercise more frequently and helped them decrease their body-mass index, according to new research from the USC School of Cinematic Arts, the Keck School of Medicine of USC, the USC School of Social Work and the University at Buffalo, SUNY.
› Verified 9 days ago
| Entity Name | Thorek Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1982643961 PECOS PAC ID: 4981593399 Enrollment ID: O20040313000143 |
News Archive
St. Jude Children's Research Hospital scientists looking for drugs to improve survival of children with high-risk neuroblastoma found a promising candidate in CX-5461.
Replacing confusing language and icons on standard warnings labels for prescription medicine and listing only the most important warnings could make a big difference in how well patients understand the instructions that are critical to their health, according to a new study from Northwestern University Feinberg School of Medicine.
Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced the initiation of a Phase 2 clinical trial with ACE-031 in patients with Duchenne Muscular Dystrophy (DMD), a fatal neuromuscular disease. ACE-031 is an investigational protein therapeutic that builds muscle and increases strength by inhibiting signaling of a cell surface receptor called the activin receptor type IIB (ActRIIB).
DigiPath, Inc., the independent digital pathology and cannabis testing, education, and media firm, has entered into a preferred supplier marketing and resource-sharing agreement with Blue Line Protection Group.
Adding social gaming elements to a behavior tracking program led people to exercise more frequently and helped them decrease their body-mass index, according to new research from the USC School of Cinematic Arts, the Keck School of Medicine of USC, the USC School of Social Work and the University at Buffalo, SUNY.
› Verified 9 days ago
| Entity Name | Northwest Neurology, Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427094077 PECOS PAC ID: 8729069158 Enrollment ID: O20040601000222 |
News Archive
St. Jude Children's Research Hospital scientists looking for drugs to improve survival of children with high-risk neuroblastoma found a promising candidate in CX-5461.
Replacing confusing language and icons on standard warnings labels for prescription medicine and listing only the most important warnings could make a big difference in how well patients understand the instructions that are critical to their health, according to a new study from Northwestern University Feinberg School of Medicine.
Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced the initiation of a Phase 2 clinical trial with ACE-031 in patients with Duchenne Muscular Dystrophy (DMD), a fatal neuromuscular disease. ACE-031 is an investigational protein therapeutic that builds muscle and increases strength by inhibiting signaling of a cell surface receptor called the activin receptor type IIB (ActRIIB).
DigiPath, Inc., the independent digital pathology and cannabis testing, education, and media firm, has entered into a preferred supplier marketing and resource-sharing agreement with Blue Line Protection Group.
Adding social gaming elements to a behavior tracking program led people to exercise more frequently and helped them decrease their body-mass index, according to new research from the USC School of Cinematic Arts, the Keck School of Medicine of USC, the USC School of Social Work and the University at Buffalo, SUNY.
› Verified 9 days ago
| Entity Name | Advanced Physicians Sc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1124075288 PECOS PAC ID: 6103879713 Enrollment ID: O20050223000649 |
News Archive
St. Jude Children's Research Hospital scientists looking for drugs to improve survival of children with high-risk neuroblastoma found a promising candidate in CX-5461.
Replacing confusing language and icons on standard warnings labels for prescription medicine and listing only the most important warnings could make a big difference in how well patients understand the instructions that are critical to their health, according to a new study from Northwestern University Feinberg School of Medicine.
Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced the initiation of a Phase 2 clinical trial with ACE-031 in patients with Duchenne Muscular Dystrophy (DMD), a fatal neuromuscular disease. ACE-031 is an investigational protein therapeutic that builds muscle and increases strength by inhibiting signaling of a cell surface receptor called the activin receptor type IIB (ActRIIB).
DigiPath, Inc., the independent digital pathology and cannabis testing, education, and media firm, has entered into a preferred supplier marketing and resource-sharing agreement with Blue Line Protection Group.
Adding social gaming elements to a behavior tracking program led people to exercise more frequently and helped them decrease their body-mass index, according to new research from the USC School of Cinematic Arts, the Keck School of Medicine of USC, the USC School of Social Work and the University at Buffalo, SUNY.
› Verified 9 days ago
| Entity Name | Integrated Rehab Consultants Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528379195 PECOS PAC ID: 7810184892 Enrollment ID: O20101203000704 |
News Archive
St. Jude Children's Research Hospital scientists looking for drugs to improve survival of children with high-risk neuroblastoma found a promising candidate in CX-5461.
Replacing confusing language and icons on standard warnings labels for prescription medicine and listing only the most important warnings could make a big difference in how well patients understand the instructions that are critical to their health, according to a new study from Northwestern University Feinberg School of Medicine.
Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced the initiation of a Phase 2 clinical trial with ACE-031 in patients with Duchenne Muscular Dystrophy (DMD), a fatal neuromuscular disease. ACE-031 is an investigational protein therapeutic that builds muscle and increases strength by inhibiting signaling of a cell surface receptor called the activin receptor type IIB (ActRIIB).
DigiPath, Inc., the independent digital pathology and cannabis testing, education, and media firm, has entered into a preferred supplier marketing and resource-sharing agreement with Blue Line Protection Group.
Adding social gaming elements to a behavior tracking program led people to exercise more frequently and helped them decrease their body-mass index, according to new research from the USC School of Cinematic Arts, the Keck School of Medicine of USC, the USC School of Social Work and the University at Buffalo, SUNY.
› Verified 9 days ago
| Entity Name | Pinnacle Pain Management Specialists Sc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932496726 PECOS PAC ID: 4880866045 Enrollment ID: O20111012000063 |
News Archive
St. Jude Children's Research Hospital scientists looking for drugs to improve survival of children with high-risk neuroblastoma found a promising candidate in CX-5461.
Replacing confusing language and icons on standard warnings labels for prescription medicine and listing only the most important warnings could make a big difference in how well patients understand the instructions that are critical to their health, according to a new study from Northwestern University Feinberg School of Medicine.
Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced the initiation of a Phase 2 clinical trial with ACE-031 in patients with Duchenne Muscular Dystrophy (DMD), a fatal neuromuscular disease. ACE-031 is an investigational protein therapeutic that builds muscle and increases strength by inhibiting signaling of a cell surface receptor called the activin receptor type IIB (ActRIIB).
DigiPath, Inc., the independent digital pathology and cannabis testing, education, and media firm, has entered into a preferred supplier marketing and resource-sharing agreement with Blue Line Protection Group.
Adding social gaming elements to a behavior tracking program led people to exercise more frequently and helped them decrease their body-mass index, according to new research from the USC School of Cinematic Arts, the Keck School of Medicine of USC, the USC School of Social Work and the University at Buffalo, SUNY.
› Verified 9 days ago
| Entity Name | Pain Relief Institute Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003364233 PECOS PAC ID: 3375822406 Enrollment ID: O20161114001391 |
News Archive
St. Jude Children's Research Hospital scientists looking for drugs to improve survival of children with high-risk neuroblastoma found a promising candidate in CX-5461.
Replacing confusing language and icons on standard warnings labels for prescription medicine and listing only the most important warnings could make a big difference in how well patients understand the instructions that are critical to their health, according to a new study from Northwestern University Feinberg School of Medicine.
Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced the initiation of a Phase 2 clinical trial with ACE-031 in patients with Duchenne Muscular Dystrophy (DMD), a fatal neuromuscular disease. ACE-031 is an investigational protein therapeutic that builds muscle and increases strength by inhibiting signaling of a cell surface receptor called the activin receptor type IIB (ActRIIB).
DigiPath, Inc., the independent digital pathology and cannabis testing, education, and media firm, has entered into a preferred supplier marketing and resource-sharing agreement with Blue Line Protection Group.
Adding social gaming elements to a behavior tracking program led people to exercise more frequently and helped them decrease their body-mass index, according to new research from the USC School of Cinematic Arts, the Keck School of Medicine of USC, the USC School of Social Work and the University at Buffalo, SUNY.
› Verified 9 days ago
| Entity Name | Laser Spine Center Of Chicago Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801303714 PECOS PAC ID: 4880959543 Enrollment ID: O20180530000336 |
News Archive
St. Jude Children's Research Hospital scientists looking for drugs to improve survival of children with high-risk neuroblastoma found a promising candidate in CX-5461.
Replacing confusing language and icons on standard warnings labels for prescription medicine and listing only the most important warnings could make a big difference in how well patients understand the instructions that are critical to their health, according to a new study from Northwestern University Feinberg School of Medicine.
Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced the initiation of a Phase 2 clinical trial with ACE-031 in patients with Duchenne Muscular Dystrophy (DMD), a fatal neuromuscular disease. ACE-031 is an investigational protein therapeutic that builds muscle and increases strength by inhibiting signaling of a cell surface receptor called the activin receptor type IIB (ActRIIB).
DigiPath, Inc., the independent digital pathology and cannabis testing, education, and media firm, has entered into a preferred supplier marketing and resource-sharing agreement with Blue Line Protection Group.
Adding social gaming elements to a behavior tracking program led people to exercise more frequently and helped them decrease their body-mass index, according to new research from the USC School of Cinematic Arts, the Keck School of Medicine of USC, the USC School of Social Work and the University at Buffalo, SUNY.
› Verified 9 days ago
| Entity Name | Perspective Behavioral And Pain Solutions Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1326671702 PECOS PAC ID: 1951732106 Enrollment ID: O20200504001274 |
News Archive
St. Jude Children's Research Hospital scientists looking for drugs to improve survival of children with high-risk neuroblastoma found a promising candidate in CX-5461.
Replacing confusing language and icons on standard warnings labels for prescription medicine and listing only the most important warnings could make a big difference in how well patients understand the instructions that are critical to their health, according to a new study from Northwestern University Feinberg School of Medicine.
Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced the initiation of a Phase 2 clinical trial with ACE-031 in patients with Duchenne Muscular Dystrophy (DMD), a fatal neuromuscular disease. ACE-031 is an investigational protein therapeutic that builds muscle and increases strength by inhibiting signaling of a cell surface receptor called the activin receptor type IIB (ActRIIB).
DigiPath, Inc., the independent digital pathology and cannabis testing, education, and media firm, has entered into a preferred supplier marketing and resource-sharing agreement with Blue Line Protection Group.
Adding social gaming elements to a behavior tracking program led people to exercise more frequently and helped them decrease their body-mass index, according to new research from the USC School of Cinematic Arts, the Keck School of Medicine of USC, the USC School of Social Work and the University at Buffalo, SUNY.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr David B Rosania, MD 908 N Elm St Ste 301, Hinsdale, IL 60521-3625 Ph: (630) 794-9999 | Dr David B Rosania, MD 908 N Elm St Ste 301, Hinsdale, IL 60521-3625 Ph: (630) 794-9999 |
News Archive
St. Jude Children's Research Hospital scientists looking for drugs to improve survival of children with high-risk neuroblastoma found a promising candidate in CX-5461.
Replacing confusing language and icons on standard warnings labels for prescription medicine and listing only the most important warnings could make a big difference in how well patients understand the instructions that are critical to their health, according to a new study from Northwestern University Feinberg School of Medicine.
Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced the initiation of a Phase 2 clinical trial with ACE-031 in patients with Duchenne Muscular Dystrophy (DMD), a fatal neuromuscular disease. ACE-031 is an investigational protein therapeutic that builds muscle and increases strength by inhibiting signaling of a cell surface receptor called the activin receptor type IIB (ActRIIB).
DigiPath, Inc., the independent digital pathology and cannabis testing, education, and media firm, has entered into a preferred supplier marketing and resource-sharing agreement with Blue Line Protection Group.
Adding social gaming elements to a behavior tracking program led people to exercise more frequently and helped them decrease their body-mass index, according to new research from the USC School of Cinematic Arts, the Keck School of Medicine of USC, the USC School of Social Work and the University at Buffalo, SUNY.
› Verified 9 days ago
Dr. Marie Kirincic, M.D. Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 550 W Ogden Ave, Hinsdale, IL 60521 Phone: 630-323-6116 Fax: 630-323-6169 | |
Christopher B. Morgan, M.D. Physical Medicine & Rehabilitation Medicare: Medicare Enrolled Practice Location: 908 N. Elm Street, Suite 109, Hinsdale, IL 60521 Phone: 630-794-9999 Fax: 630-794-9998 | |
Alexandra Magaletta, DPT Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 777 N York Rd, Hinsdale, IL 60521 Phone: 630-819-8384 | |
Valerie Y Ito, MD Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 5601 S County Line Rd, Hinsdale, IL 60521 Phone: 630-286-4246 | |
Collins Fitzpatrick, MD Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 5601 S County Line Rd, Hinsdale, IL 60521 Phone: 630-286-4246 |